ArticleJBMR plus2025
Overexpression of interleukin-4 using adeno-associated virus is a potential strategy to enhance bone regeneration.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Osteoimmunologic Basis of Biologic and Bioengineered Scaffolds in Fracture Healing.Bioengineering (Basel, Switzerland) · 2026Review
- Development of a gene-activated matrix for enhanced AAV gene deliveryFrontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the bone regeneration potential of IL-4 gene delivery via adeno-associated virus (AAV) vectors, with a particular focus on modulating macrophage polarization and promoting osteogenic differentiation. Four different AAV serotypes (AAV1, AAV2, AAV5, and AAV6) encoding the IL-4 gene were evaluated in rat and human gingival fibroblasts and dental pulp stem cells (DPSCs). AAV2 exhibited the highest transduction efficiency and IL-4 expression in all tested cell types. IL-4 transduced DPSCs demonstrated enhanced osteogenic differentiation, as evidenced by the upregulation of osteogenic markers, increased alkaline phosphatase activity, and elevated calcium deposition. IL-4 transduction activated the extracellular signal-regulated kinase signaling pathway, contributing to osteogenesis. To assess the therapeutic efficacy of AAV2-IL-4 in vivo, a lipopolysaccharide-induced calvarial osteolysis model was established in C57BL/6 mice. AAV2-IL-4 administration significantly reduced bone resorption, as confirmed by micro-CT and histological analysis. Moreover, IL-4 gene delivery promoted M2 macrophage polarization. These findings highlight AAV2-IL-4 as a promising gene therapy strategy for bone regeneration, effectively integrating immunomodulation and osteogenesis to counteract inflammation-driven bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.